Maxim analyst Jason McCarthy lowered the firm’s price target on MetaVia (MTVA) to $3 from $6 and keeps a Buy rating on the shares. The firm cites the company’s Q1 results, cash update, and its recent $10M financing in adjusting its model, though it remains positive on MetaVia’s obesity (DA-1726) and MASH (DA-1241) treatment opportunities, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTVA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue